PROMISE Score: Ruling Out Heart Disease in Chest Pain Patients

A newly refined risk score may allow a significant number of patients experiencing stable chest pain to avoid unnecessary cardiac testing, according to research published in August 2022 in JACC: Cardiovascular Imaging. The PROMISE minimal risk score (PMRS) aims to identify individuals with a highly low likelihood of significant coronary artery disease (CAD) and subsequent adverse cardiac events, potentially reducing both healthcare costs and patient anxiety.

Understanding the Challenge of Chest Pain Evaluation

Chest pain is a common reason for seeking medical attention, but determining whether it signals a life-threatening heart problem or a less serious issue can be complex. Current guidelines recommend estimating a patient’s ‘pretest probability’ (PTP) of obstructive CAD – essentially, how likely they are to have blocked arteries – to guide further testing. Though, these guidelines offer limited clarity on the best course of action for patients falling into an intermediate risk category, those with a PTP between 5% and 15%. This represents where the PROMISE minimal risk score comes into play.

Coronary artery disease, a condition where plaque builds up inside the heart’s arteries, can lead to angina (chest pain) and, more seriously, heart attack. Diagnosing CAD typically involves tests like stress tests, CT scans, or invasive angiography. These tests aren’t without risks and can be expensive. The goal of the PMRS is to safely reduce the number of patients undergoing these procedures.

How the PROMISE Minimal Risk Score Works

The PMRS was developed using data from two large clinical trials: PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) and Dan-NICAD (Danish study of Non-Invasive Testing in Coronary Artery Disease). Researchers analyzed data from over 13,000 patients with stable chest pain and a PTP of greater than 5% to 15%. They identified a PMRS cutoff of 34 or higher that corresponded to a prevalence of obstructive CAD of 5% or less.

patients with a PMRS of 34 or above are considered to have a low enough risk that further invasive testing may not be necessary. The study found that applying this cutoff down-classified approximately 32% of patients in the intermediate risk category, and the prevalence of obstructive CAD in this down-classified group was only 3.2%, compared to 7.1% in those who weren’t down-classified. You can find more details about the PROMISE trial itself here.

Beyond Diagnosis: Assessing Prognostic Impact

The research didn’t stop at simply identifying low-risk patients. Researchers also investigated whether a higher PMRS (≥34) was associated with a lower risk of future heart attacks or death. While the results weren’t statistically significant, they did suggest a trend towards a reduced risk of myocardial infarction and death in patients with a PMRS of 34 or higher (Hazard Ratio: 0.58, 95% Confidence Interval: 0.29-1.16). This indicates that the score may not only help avoid unnecessary tests but also identify patients who are generally at lower risk for cardiac events. Further research is needed to confirm this prognostic value.

What Does This Mean for Patients?

This research doesn’t mean everyone with chest pain can skip cardiac testing. It specifically applies to patients with stable chest pain – meaning the pain is predictable and occurs with exertion, and is relieved by rest – and a pretest probability of obstructive CAD between 5% and 15%. It’s crucial to remember that chest pain can be a symptom of many different conditions, some of which are serious and require immediate attention.

If you experience new or worsening chest pain, especially if it’s accompanied by shortness of breath, sweating, nausea, or pain radiating to your arm or jaw, seek medical attention immediately. A qualified clinician will assess your individual risk factors and determine the appropriate course of action. The PMRS is a tool to aid in that assessment, not a substitute for professional medical judgment.

Limitations and Future Directions

Like all research, this study has limitations. The data was derived from two specific clinical trials, and it’s possible the PMRS may not perform as well in different populations or healthcare settings. The confidence interval for the prognostic impact (HR 0.58, 95% CI 0.29-1.16) is relatively wide, meaning the observed effect could be due to chance.

Researchers are continuing to investigate the PMRS and its potential applications. Ongoing studies are exploring whether the score can be integrated into clinical decision support tools to help physicians more accurately assess and manage patients with suspected CAD. You can read more about the study’s findings in the National Institutes of Health’s PubMed database. The goal is to refine the score and validate its performance across diverse patient populations, ultimately leading to more efficient and effective cardiac care. The score also offers an alternative to traditional pretest probability models, as detailed in this article on ScienceDirect.

What comes next: The researchers emphasize the require for further validation of the PMRS in real-world clinical practice. This will involve prospective studies that track patients managed using the score to assess its impact on healthcare utilization, costs, and patient outcomes. Guidance from cardiology societies will likely evolve as more data become available.